Publication:
A Spectral Graph Regression Model for Learning Brain Connectivity of Alzheimer’s Disease

Thumbnail Image

Open/View Files

Date

2015

Journal Title

Journal ISSN

Volume Title

Publisher

Public Library of Science
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Hu, Chenhui, Lin Cheng, Jorge Sepulcre, Keith A. Johnson, Georges E. Fakhri, Yue M. Lu, and Quanzheng Li. 2015. “A Spectral Graph Regression Model for Learning Brain Connectivity of Alzheimer’s Disease.” PLoS ONE 10 (5): e0128136. doi:10.1371/journal.pone.0128136. http://dx.doi.org/10.1371/journal.pone.0128136.

Research Data

Abstract

Understanding network features of brain pathology is essential to reveal underpinnings of neurodegenerative diseases. In this paper, we introduce a novel graph regression model (GRM) for learning structural brain connectivity of Alzheimer's disease (AD) measured by amyloid-β deposits. The proposed GRM regards 11C-labeled Pittsburgh Compound-B (PiB) positron emission tomography (PET) imaging data as smooth signals defined on an unknown graph. This graph is then estimated through an optimization framework, which fits the graph to the data with an adjustable level of uniformity of the connection weights. Under the assumed data model, results based on simulated data illustrate that our approach can accurately reconstruct the underlying network, often with better reconstruction than those obtained by both sample correlation and ℓ1-regularized partial correlation estimation. Evaluations performed upon PiB-PET imaging data of 30 AD and 40 elderly normal control (NC) subjects demonstrate that the connectivity patterns revealed by the GRM are easy to interpret and consistent with known pathology. Moreover, the hubs of the reconstructed networks match the cortical hubs given by functional MRI. The discriminative network features including both global connectivity measurements and degree statistics of specific nodes discovered from the AD and NC amyloid-beta networks provide new potential biomarkers for preclinical and clinical AD.

Description

Keywords

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Referenced By

Related Stories